- About Us
- Nano-Social Network
- Nano Consulting
- My Account
Gene therapy holds promise in the treatment of cancer as well as a large number of other diseases. However, developing a scalable system for delivering genes to cells both efficiently and safely has been challenging. Now, two teams of researchers have developed versatile nanotechnology-enabled platforms that could get therapeutic genes safely and efficiently into cancer cells.
In one study, a team of Northwestern University researchers has shown that nanodiamonds can serve as a novel gene delivery technology that combines key enhanced delivery efficiency along with outstanding biocompatibility, all in one drug delivery package. "Finding a more efficient and biocompatible method for gene delivery than is currently available is a major challenge in medicine," said Dean Ho, Ph.D., who led the research. "By harnessing the innate advantages of nanodiamonds, we now have demonstrated their promise for gene therapy."
Dr. Ho and his research team engineered surface-modified nanodiamond particles that successfully and efficiently delivered DNA into mammalian cells. The delivery efficiency was 70 times greater than that of a conventional standard for gene delivery. The results of these experiments were published in the journal ACS Nano. Dr. Ho and his research team originally demonstrated the application of nanodiamonds for chemotherapeutic delivery (click here for an earlier story).
Multiple barriers confront conventional approaches, making it difficult to integrate both high-efficiency delivery and biocompatibility into one gene delivery system. But the Northwestern researchers were able to do just that by functionalizing the nanodiamond surface with a low-molecular-weight polymer known as PEI800. PEI800 is currently used in gene therapy clinical trials, and although it is biocompatible, it does not deliver DNA to cells with high efficiency. The combination of PEI800 and nanodiamonds produced a 70-fold enhancement in delivery efficiency over PEI800 alone, and the biocompatibility of PEI800 was preserved. The process is highly scalable, which holds promise for translational capability.
The researchers used a human cervical cancer cell line called HeLa to test the efficiency of gene delivery using the functionalized nanodiamonds. Glowing green cells confirmed the delivery and insertion into the cells of a DNA sequence that codes for green fluorescent protein. This experiment served as a demonstrative model of how specific disease-fighting DNA strands could be delivered to cells.
About National Cancer Institute
To help meet the goal of reducing the burden of cancer, the National Cancer Institute (NCI), part of the National Institutes of Health, is engaged in efforts to harness the power of nanotechnology to radically change the way we diagnose, treat and prevent cancer.
The NCI Alliance for Nanotechnology in Cancer is a comprehensive, systematized initiative encompassing the public and private sectors, designed to accelerate the application of the best capabilities of nanotechnology to cancer.
Currently, scientists are limited in their ability to turn promising molecular discoveries into benefits for cancer patients. Nanotechnology can provide the technical power and tools that will enable those developing new diagnostics, therapeutics, and preventives to keep pace with today’s explosion in knowledge.
For more information, please click here
National Cancer Institute
Office of Technology & Industrial Relations
ATTN: NCI Alliance for Nanotechnology in Cancer
Building 31, Room 10A49
31 Center Drive , MSC 2580
Bethesda , MD 20892-2580
Copyright © National Cancer InstituteIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Argon is not the 'dope' for metallic hydrogen March 24th, 2017
ATTOPSEMI Technology Joins FDXcelerator Program to Deliver Advanced Non-Volatile Memory IP to GLOBALFOUNDRIES 22 FDX® Technology Platform: Leading-edge I-fuse™ brings higher reliability, smaller cell size and ease of programmability for consumer, automotive, and IoT applications March 27th, 2017